Open AccessAn Immune-modulating Diet Maintains Food Intake during Cancer Chemotherapy
Author(s) -
Naoki Nakaya,
Kentaro Nakamura,
Hidekazu Tonouchi,
Yasutaka Senpuku,
Mami Muramatsu,
Yuichi Takemasa,
Ayako Izumi,
Aya Tsuchiya,
Setsuo Ota,
Itaru Sato,
Keita Koizumi,
Hideo Nakajima
Publication year - 2023
Publication title -
medical and clinical research
Language(s) - English
Resource type - Journals
ISSN - 2577-8005
DOI - 10.33140/mcr.05.09.07
Subject(s) - ghrelin , enteral administration , chemotherapy , immune system , medicine , cancer , calorie , parenteral nutrition , colorectal cancer , endocrinology , lymphoma , immunology , hormone
An immune-modulating diet (IMD), an enteral diet enriched with immunonutrition andwhey-hydrolyzed peptides, has been shown to bring an improvement of prognosis bysuppressing inflammation after surgery or under stress. In this study, we haveexperimentally and clinically examined the effect of the IMD in cancer chemotherapy. Inexperiments using colorectal cancer cell-transplanted mice, the mice fed with the IMD incombination with anti-cancer agent showed significantly to maintain their body weightexcluding tumor, and to reduce plasma interleukin-6 (IL-6) levels compared with thecontrol group. Furthermore, normal mice fed with the IMD elevated the level of plasmaghrelin, in particular acyl ghrelin. An clinical trial for a patient with malignantlymphoma revealed that the acyl/desacyl ghrelin ratio and total calorie intake wasincreased when the patient was supplemented with the IMD in conjunction withchemotherapy. These results suggested that the supplementation of the IMD during cancerchemotherapy might enable to maintain the food intake of the patients through elevatingtheir acyl ghrelin levels